The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy

Abstract Background While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain...

Full description

Bibliographic Details
Main Authors:	Tsung-Han Tsai, Po-Jung Su, Shih-Yu Huang, Ming-Chun Kuo, Chang-Ting Lin, Chia-Che Wu, Hao-Lun Luo, Chien-Hsu Chen, Chih-Chi Chou, Ting-Ting Liu, Chun-Chieh Huang, Kai-Lung Tsai, Yu-Li Su
Format:	Article
Language:	English
Published:	BMC 2023-09-01
Series:	BMC Cancer
Subjects:	Metastatic urothelial carcinoma Variant histology Immune checkpoint inhibitors Real-world data
Online Access:	https://doi.org/10.1186/s12885-023-11398-w

Similar Items

Progress in immune checkpoint inhibitor-based combined regimens in the treatment of metastatic urothelial carcinoma
by: Liu Jianbing, Yue Zhongjin, Shang Panfeng, Liu Yating, Chang Hong
Published: (2023-09-01)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018-01-01)

Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature
by: Christian Fuhrmann, et al.
Published: (2020-05-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis
by: Felix Riedel, et al.
Published: (2022-06-01)

Variant Histology: The Impact on Oncological Outcomes of Patients with Urothelial Carcinoma of The Bladder Treated with Radical Cystectomy
by: Berk Hazır, et al.
Published: (2021-12-01)

Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
by: Akinori Minato, et al.
Published: (2024-02-01)

Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions
by: Yuki Endo, et al.
Published: (2024-01-01)

Variant histologies of urothelial carcinoma: Does it change the survival outcomes in patients managed with radical cystectomy?
by: João Nuno Pereira, et al.
Published: (2022-06-01)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
by: Chung-Ying Tsai, et al.
Published: (2021-12-01)

Radical cystectomy for bladder urothelial carcinoma with aggressive variant histology
by: Vahid Mehrnoush, et al.
Published: (2022-09-01)

Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review
by: Kangxin Ni, et al.
Published: (2023-05-01)

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
by: Alessandro Rizzo, et al.
Published: (2022-02-01)

Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data
by: Fischer C, et al.
Published: (2020-06-01)

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors
by: Jean-Michel Lavoie, et al.
Published: (2021-11-01)

Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
by: Hsiao-Ling Chen, et al.
Published: (2021-03-01)

Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis
by: Chi-Wen Lo, et al.
Published: (2022-04-01)

Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
by: Li-Yu Yang, et al.
Published: (2024-03-01)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
by: Siteng Chen, et al.
Published: (2020-08-01)

Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma
by: Hao-Lun Luo, et al.
Published: (2019-04-01)

Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma
by: LYU Zhengqin, et al.
Published: (2024-03-01)

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
by: Lilong Zhang, et al.
Published: (2022-09-01)

Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
by: Giulia Bonfante, et al.
Published: (2021-01-01)

Fine needle aspiration cytology of metastatic urothelial carcinoma: Study of seven cases with review of literature
by: Gagandeep Kaur, et al.
Published: (2012-01-01)

Poor Outcome due to the Plasmacytoid Variant of Urothelial Carcinoma
by: Kyotaro Fukuta, et al.
Published: (2022-03-01)

Homologous Recombination Related Signatures Predict Prognosis and Immunotherapy Response in Metastatic Urothelial Carcinoma
by: Pan Li, et al.
Published: (2022-04-01)

The Impact of Variant Histology in Patients with Urothelial Carcinoma Treated with Radical Cystectomy: Can We Predict the Presence of Variant Histology?
by: Nebojsa Prijovic, et al.
Published: (2023-09-01)

Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy
by: Andrea Katharina Lindner, et al.
Published: (2023-06-01)

A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
by: Yung-Hao Liu, et al.
Published: (2021-09-01)

Superior vena cava syndrome due to metastasis from urothelial cancer: A case report and literature review
by: Hironobu Wakeda, et al.
Published: (2013-01-01)

Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma
by: Wenqin Feng, et al.
Published: (2022-05-01)

A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome
by: Ryosuke Oki, et al.
Published: (2023-01-01)

Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort
by: Anke Richters, et al.
Published: (2024-01-01)

Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients
by: Elena Sevillano Fernández, et al.
Published: (2022-08-01)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
by: Takashi Kawahara, et al.
Published: (2023-08-01)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
by: Akiko Ishii, et al.
Published: (2020-06-01)

Urothelial carcinoma arising from an ovarian mature cystic teratoma
by: Hui-Yu Chuang, et al.
Published: (2015-08-01)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
by: Bunpei Isoda, et al.
Published: (2023-06-01)

Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants
by: Yu Fan, et al.
Published: (2022-04-01)

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
by: Dietrich B, et al.
Published: (2018-01-01)